Drug Trial Radar · NCT07334249
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Jun 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.
Conditions
- Major Depressive Disorder, Healthy Volunteer
Interventions
SP-101 injectionDrug
SP-101 is non-competitive antagonist against NMDA receptor and is administered by intravenous infusion.
PlaceboDrug
Participants will be randomly assigned to the experimental group and placebo groups at ratio of 3:1. Participants assigned to the experimental group will be administered SP-101 by intravenous infusion. Accordingly, participants assigned to the placebo group will be administered placebo by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse Events, throughout study completionTime frame: Through study completion, an average of 10 days for SAD and an average of 28 days for MAD
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center (SMHC)
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.